1.3　References

1.3　References

［1］Lindsey A.Torre，Freddie Bray，Rebecca L.Siegel，et al.Global Cancer Statistics，2012.CA CANCER J CLIN，2015，65：87-108.

［2］Freddie Bray，Jacques Ferlay，Isabelle Soerjomataram，et al.Global Cancer Statistics 2018：GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA CANCER J CLIN，2018，68：394-424.

［3］Ahmedin Jemal，Freddie Bray，Melissa M，et al.Global Cancer Statistics.CA CANCER J CLIN，2011，61：69-90.

［4］Chen S，Parmigiani G.Meta-analysis of BRCA1 and BRCA2 penetrance.J Clin Oncol，2007，25（11）：1329-1333.

［5］Antoniou A，Pharoah PD，Narod S，et al.Average risks of breast and ovarian cancer associated withBRCA1 or BRCA2 mutations detected in case Series unselected for family history：a combined analysis of 22 studies.Am J Hum Genet，2003，72（5）：1117-1130.

［6］Ziegler RG，Hoover RN，Pike MC，et al.Migration patterns and breast cancer risk in Asian-American women.J Natl Cancer Inst.1993，85：1819-1827.

［7］Islami F，Chen W，Yu XQ，et al.Cancer deaths and cases attributable to lifestyle factors and infections in China，2013［J］.Ann Oncol，2017，28（10）：2567-2574.

［8］Brinton LA，Gaudet MM，Gierach GL.Breast cancer.In：Thun MJ，Linet MS，Cerhan JR，Haiman CA，Schottenfeld D，eds.Cancer Epidemiology and Prevention.4th ed.New York：Oxford University Press，2018：861-888.

［9］Bray F，McCarron P，Parkin DM.The changing global patterns of female breast cancer incidence and mortality.Breast Cancer Res.2004，6：229-239.

［10］Ravdin PM，Cronin KA，Howlader N，et al.The decrease in breast-cancer incidence in 2003 in the United States.N Engl J Med.2007，356：1670-1674.

［11］Rossouw JE，Anderson GL，Prentice RL，et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women：principal results from the Women's Health Initiative randomized controlled trial.JAMA 2002，288：321-333.(https://www.daowen.com)

［12］Schopper D，Wolf C.How effective are breast cancer screening programmers by mammography？Review of the current evidence.Eur J Cancer，2009，45（11）：1916-1923.

［13］Qaseem A，Lin JS，Mustafa RA，et al.Screening for Breast Cancer in Average-Risk Women：A Guidance Statement From the American College of Physicians.Ann Intern Med，2019 Apr 9.

［14］NCCN Clinical Practice Guidelines In Oncology.Breast Cancer Screening and Diagnosis，2019.

［15］Lakhani SR，Ellis IO，Schnitt SJ，et aL.WHO classification of tumours of the breast.Lyon，France：IARC Press，2012.

［16］Tavassoli FA，Devilee P.Pathology and genetics of tumors of the breast and female genital organs.Lyon，France：IARC Press，2003.

［17］AJCC Cancer Staging Manual Eighth Edition，American Joint Committee on Cancer，2017.DO1 10.1007/978-3-319-40618-3.

［18］孙可欣，郑荣寿，张思维，等.2015年中国分地区恶性肿瘤发病和死亡分析［J］.中国肿瘤，2019，28（01）：1-11.

［19］张敏璐，彭鹏，吴春晓，等.2008-2012年中国肿瘤登记地区女性乳腺癌发病和死亡分析［J］.中华肿瘤，2019，41（4）：315-320.

［20］中国抗癌协会，国家肿瘤临床医学研究中心.中国女性乳腺癌筛查指南［J］.中国肿瘤临床，2019，46（9）：429-431.

［21］陈孝平，汪建平.外科学.8版［M］.北京：人民卫生出版社，2013：256-260.